Insulet Corp. stock falls for fourth consecutive day amid market downturn

8 articles · Updated · MarketWatch · Apr 28

Shares dropped 2.89% to $182.87 on Tuesday, with trading volume reaching 1.2 million, above the 50-day average.
Insulet underperformed the S&P 500 and Dow Jones, and lagged behind competitors like Eli Lilly and Johnson & Johnson, both of which posted gains.
The stock now sits 48.47% below its 52-week high of $354.88, reflecting ongoing investor concerns during a broadly negative market session.

With its stock nearly halved, is Insulet a bargain or a falling knife?

Can Insulet's global expansion offset its mounting legal and safety issues at home?

Can Insulet's next-gen 'Omnipod 6' be enough to win back patient trust?

Did Insulet executives mislead investors about product flaws before the recall?

Will the rise of new GLP-1 drugs make insulin pumps like Omnipod obsolete?